Lenalidomide maintenance in high risk chronic lymphocytic leukaemia: practice changing study or hypothesis generating approach?

Lancet Haematol. 2017 Oct;4(10):e455-e456. doi: 10.1016/S2352-3026(17)30178-3. Epub 2017 Sep 12.

Authors

Davide Rossi¹, Adalgisa Condoluci²

Affiliations

¹ Department of Hematology, Institute of Oncology Research, 6500 Bellinzona, Switzerland. Electronic address: davide.rossi@eoc.ch.
² Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland.

PMID: 28916312
DOI: 10.1016/S2352-3026(17)30178-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents
Humans
Lenalidomide
Leukemia, Lymphocytic, Chronic, B-Cell*
Thalidomide* / analogs & derivatives

Substances

Antineoplastic Agents
Thalidomide
Lenalidomide